New Drug's breast milk levels under the microscope
NCT ID NCT07669077
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This early-stage study will give a single dose of nipocalimab to 8 healthy breastfeeding women and measure how much of the drug appears in their breast milk over 8 days. The goal is to understand the drug's transfer into breast milk, which is important for future safety recommendations. No treatment is being tested; it is purely a measurement study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nipocalimab
- What this could lead to
- If successful, this study will show how much nipocalimab passes into breast milk, helping guide safe use during breastfeeding.
- What could go wrong
- This is a very small, early-phase study in healthy women, not patients. Results may not apply to all situations or predict long-term effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test